Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.

Tytuł:
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
Autorzy:
Ramamurthy R; University of Washington School of Medicine, Seattle, Washington.
Hughes M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Children's Hospital, Seattle, Washington.
Morris V; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Bolouri H; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Gerbing RB; Children's Oncology Group, Monrovia, California.
Wang YC; Children's Oncology Group, Monrovia, California.
Loken MR; Hematologics, Inc, Seattle, Washington.
Raimondi SC; Children's Oncology Group, Monrovia, California.; Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Hirsch BA; Children's Oncology Group, Monrovia, California.; Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota.
Gamis AS; Children's Oncology Group, Monrovia, California.; Children's Mercy Hospitals & Clinics, Kansas City, Missiouri.
Oehler VG; University of Washington School of Medicine, Seattle, Washington.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Alonzo TA; Keck School of Medical Department of Preventive Medicine, University of Southern California, Los Angeles, California.
Meshinchi S; University of Washington School of Medicine, Seattle, Washington. .; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. .; Seattle Children's Hospital, Seattle, Washington. .; Children's Oncology Group, Monrovia, California. .
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2016 Dec; Vol. 63 (12), pp. 2096-2103. Date of Electronic Publication: 2016 Aug 11.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Hoboken, N.J. : John Wiley, c 2004-
MeSH Terms:
Leukemia, Myeloid, Acute/*genetics
MicroRNAs/*analysis
Adolescent ; Adult ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Leukemia, Myeloid, Acute/mortality ; Male ; fms-Like Tyrosine Kinase 3/genetics
References:
Leukemia. 2015 May;29(5):1051-9. (PMID: 25428263)
J Clin Med. 2015 Jan 09;4(1):127-49. (PMID: 26237023)
Blood. 2008 Mar 15;111(6):3183-9. (PMID: 18187662)
PLoS One. 2013;8(2):e56334. (PMID: 23418555)
Oncogene. 2013 Jun 13;32(24):2992-3000. (PMID: 22797073)
Blood. 2004 Mar 1;103(5):1676-84. (PMID: 14604967)
Haematologica. 2012 Feb;97(2):160-7. (PMID: 22058204)
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4908-13. (PMID: 21383199)
Blood. 2007 Aug 1;110(3):979-85. (PMID: 17440048)
Blood. 2011 Jan 27;117(4):1121-9. (PMID: 21045193)
J Clin Oncol. 2013 Jun 10;31(17):2086-93. (PMID: 23650424)
Int Rev Immunol. 2009;28(5):264-84. (PMID: 19811312)
Nucleic Acids Res. 2010 Sep;38(16):5472-8. (PMID: 20444872)
Leukemia. 2015 May;29(5):1004-17. (PMID: 25541152)
Blood. 2009 Aug 13;114(7):1374-82. (PMID: 19520806)
Nat Genet. 2011 Mar 20;43(4):371-8. (PMID: 21423181)
Mol Cancer. 2014 Apr 05;13:79. (PMID: 24708856)
Leukemia. 2014 Apr;28(4):804-12. (PMID: 24072101)
Leukemia. 2015 Mar;29(3):535-47. (PMID: 25092144)
J Hematol Oncol. 2012 Jun 08;5:26. (PMID: 22681934)
Immunol Rev. 2013 May;253(1):146-57. (PMID: 23550644)
Pediatr Clin North Am. 2015 Feb;62(1):75-93. (PMID: 25435113)
J Clin Oncol. 2011 Feb 10;29(5):551-65. (PMID: 21220611)
Blood. 2006 Dec 1;108(12):3654-61. (PMID: 16912228)
Blood. 2013 Feb 21;121(8):1422-31. (PMID: 23264595)
Oncogene. 2012 Sep 13;31(37):4085-94. (PMID: 22249254)
Leukemia. 2012 Apr;26(4):654-61. (PMID: 21968880)
Adv Hematol. 2014;2014:103175. (PMID: 24778653)
Biochim Biophys Acta. 2009 Jun;1792(6):497-505. (PMID: 19268705)
Oncologist. 2007 Mar;12(3):341-55. (PMID: 17405900)
J Clin Oncol. 2013 Jun 10;31(17):2065-6. (PMID: 23650415)
Cancer Res. 2005 May 1;65(9):3509-12. (PMID: 15867338)
Proc Natl Acad Sci U S A. 2009 Apr 28;106(17 ):7113-8. (PMID: 19359473)
Leukemia. 2014 May;28(5):1022-32. (PMID: 24270738)
Proc Natl Acad Sci U S A. 2007 Jan 30;104(5):1604-9. (PMID: 17242365)
N Engl J Med. 2008 May 1;358(18):1919-28. (PMID: 18450603)
J Exp Med. 2008 Mar 17;205(3):585-94. (PMID: 18299402)
Leukemia. 2010 Feb;24(2):460-6. (PMID: 19956200)
Nat Rev Drug Discov. 2013 Nov;12(11):847-65. (PMID: 24172333)
Nat Rev Mol Cell Biol. 2013 Aug;14(8):475-88. (PMID: 23800994)
PLoS One. 2009 Nov 13;4(11):e7826. (PMID: 19915715)
Leukemia. 1999 Dec;13(12):1993-9. (PMID: 10602420)
Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40. (PMID: 18832181)
Blood. 2009 Jun 25;113(26):6558-66. (PMID: 19304957)
Cancer Cell. 2010 Jan 19;17(1):13-27. (PMID: 20060365)
Grant Information:
R01 CA114563 United States CA NCI NIH HHS; U10 CA180899 United States CA NCI NIH HHS
Contributed Indexing:
Keywords: AML; children; miR-155
Substance Nomenclature:
0 (MIRN155 microRNA, human)
0 (MicroRNAs)
EC 2.7.10.1 (FLT3 protein, human)
EC 2.7.10.1 (fms-Like Tyrosine Kinase 3)
Entry Date(s):
Date Created: 20160812 Date Completed: 20170614 Latest Revision: 20191120
Update Code:
20240104
PubMed Central ID:
PMC5497493
DOI:
10.1002/pbc.26157
PMID:
27511899
Czasopismo naukowe
Background: Aberrant expression of microRNA-155 (miR-155) has been implicated in acute myeloid leukemia (AML) and associated with clinical outcome.
Procedure: We evaluated miR-155 expression in 198 children with normal karyotype AML (NK-AML) enrolled in Children's Oncology Group (COG) AML trial AAML0531 and correlated miR-155 expression levels with disease characteristics and clinical outcome. Patients were divided into quartiles (Q1-Q4) based on miR-155 expression level, and disease characteristics were then evaluated and correlated with miR-155 expression.
Results: MiR-155 expression varied over 4-log10-fold range relative to its expression in normal marrow with a median expression level of 0.825 (range 0.043-25.630) for the entire study cohort. Increasing miR-155 expression was highly associated with the presence of FLT3/ITD mutations (P < 0.001) and high-risk disease (P < 0.001) and inversely associated with standard-risk (P = 0.008) and low-risk disease (P = 0.041). Patients with highest miR-155 expression had a complete remission (CR) rate of 46% compared with 82% in low expressers (P < 0.001) with a correspondingly lower event-free (EFS) and overall survival (OS) (P < 0.001 and P = 0.002, respectively). In a multivariate model that included molecular risk factors, high miR-155 expression remained a significant independent predictor of OS (P = 0.022) and EFS (0.019).
Conclusions: High miR-155 expression is an adverse prognostic factor in pediatric NK-AML patients. Specifically, high miR-155 expression not only correlates with FLT3/ITD mutation status and high-risk disease but it is also an independent predictor of worse EFS and OS.
(© 2016 Wiley Periodicals, Inc.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies